MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer
MAPK激活预示不良预后,而MEK抑制剂Selumetinib可逆转ER阳性高级别浆液性卵巢癌的抗雌激素耐药性
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-15-0534
Hew, Karina E; Miller, Philip C; El-Ashry, Dorraya; Sun, Jun; Besser, Alexandra H; Ince, Tan A; Gu, Mengnan; Wei, Zhi; Zhang, Gao; Brafford, Patricia; Gao, Wei; Lu, Yiling; Mills, Gordon B; Slingerland, Joyce M; Simpkins, Fiona